FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004280168> ?p ?o ?g. }

• W2004280168 endingPage "869" @default.
• W2004280168 startingPage "861" @default.
• W2004280168 abstract "Advanced lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) activating mutations usually are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs), but whether EGFR-mutant lung adenocarcinoma is also responsive to pemetrexed-based chemotherapy remains controversial. We conducted a retrospective study to evaluate the efficacy and outcome of pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR mutation statuses. Sixty-nine EGFR-mutant and 89 wild-type patients with advanced lung adenocarcinoma were enrolled. They all had received pemetrexed-based treatments. Chemotherapy objective response rate (ORR), median progression-free survival (mPFS), and thymidylate synthase (TS) expression levels of EGFR-mutant patients were compared with those of EGFR-wild-type patients. For the EGFR-mutant patients treated with first-line platinum/pemetrexed combinations, the ORR was significantly higher than that of the wild-type patients treated with similar regimens (43 vs. 21 %, p = 0.039). Nonetheless, for the patients treated with pemetrexed monotherapy, the difference in ORR was not significant between patients with EGFR mutations and those with wild-type EGFR in any line of treatments (in the first-line setting 20 vs. 13 %, p = 0.715; in the second-/third-line setting 13 vs. 8 %, p = 0.655). On the other hand, the mPFS for the EGFR-mutant patients treated with first-line combinations was also obviously prolonged (8.3 vs. 6.7 months, p = 0.004). However, among the patients receiving second-line platinum/pemetrexed combinations or any line of single-agent pemetrexed, there was no difference in PFS between EGFR-mutant and wild-type patients. Our results indicated that the efficacies and outcomes of pemetrexed treatment in advanced lung adenocarcinoma patients with EGFR activating mutations were similar to those in patients with EGFR-wild-type genotype, except in the setting of first-line platinum/pemetrexed combination chemotherapy." @default.
• W2004280168 created "2016-06-24" @default.
• W2004280168 creator A5017216315 @default.
• W2004280168 creator A5036390761 @default.
• W2004280168 creator A5051363890 @default.
• W2004280168 creator A5063105342 @default.
• W2004280168 creator A5074216961 @default.
• W2004280168 creator A5080637912 @default.
• W2004280168 date "2014-10-10" @default.
• W2004280168 modified "2023-09-25" @default.
• W2004280168 title "Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes" @default.
• W2004280168 cites W1910732341 @default.
• W2004280168 cites W1974662648 @default.
• W2004280168 cites W1976565907 @default.
• W2004280168 cites W1985329793 @default.
• W2004280168 cites W1990709725 @default.
• W2004280168 cites W1994508061 @default.
• W2004280168 cites W2018586174 @default.
• W2004280168 cites W2019607817 @default.
• W2004280168 cites W2030864655 @default.
• W2004280168 cites W2041768451 @default.
• W2004280168 cites W2043696829 @default.
• W2004280168 cites W2060774265 @default.
• W2004280168 cites W2065223314 @default.
• W2004280168 cites W2082623135 @default.
• W2004280168 cites W2095618958 @default.
• W2004280168 cites W2096198395 @default.
• W2004280168 cites W2099725888 @default.
• W2004280168 cites W2110097314 @default.
• W2004280168 cites W2111662961 @default.
• W2004280168 cites W2114998251 @default.
• W2004280168 cites W2115658330 @default.
• W2004280168 cites W2125195105 @default.
• W2004280168 cites W2129360604 @default.
• W2004280168 cites W2132157071 @default.
• W2004280168 cites W2134667653 @default.
• W2004280168 cites W2145842917 @default.
• W2004280168 cites W2160982674 @default.
• W2004280168 cites W2161821474 @default.
• W2004280168 cites W2166084034 @default.
• W2004280168 doi "https://doi.org/10.1007/s13277-014-2692-4" @default.
• W2004280168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25301443" @default.
• W2004280168 hasPublicationYear "2014" @default.
• W2004280168 type Work @default.
• W2004280168 sameAs 2004280168 @default.
• W2004280168 citedByCount "7" @default.
• W2004280168 countsByYear W20042801682015 @default.
• W2004280168 countsByYear W20042801682016 @default.
• W2004280168 countsByYear W20042801682017 @default.
• W2004280168 countsByYear W20042801682018 @default.
• W2004280168 countsByYear W20042801682020 @default.
• W2004280168 countsByYear W20042801682021 @default.
• W2004280168 crossrefType "journal-article" @default.
• W2004280168 hasAuthorship W2004280168A5017216315 @default.
• W2004280168 hasAuthorship W2004280168A5036390761 @default.
• W2004280168 hasAuthorship W2004280168A5051363890 @default.
• W2004280168 hasAuthorship W2004280168A5063105342 @default.
• W2004280168 hasAuthorship W2004280168A5074216961 @default.
• W2004280168 hasAuthorship W2004280168A5080637912 @default.
• W2004280168 hasConcept C104317684 @default.
• W2004280168 hasConcept C121608353 @default.
• W2004280168 hasConcept C123321153 @default.
• W2004280168 hasConcept C126322002 @default.
• W2004280168 hasConcept C143065580 @default.
• W2004280168 hasConcept C143998085 @default.
• W2004280168 hasConcept C207583985 @default.
• W2004280168 hasConcept C2776256026 @default.
• W2004280168 hasConcept C2776694085 @default.
• W2004280168 hasConcept C2777240266 @default.
• W2004280168 hasConcept C2778239845 @default.
• W2004280168 hasConcept C2779438470 @default.
• W2004280168 hasConcept C2780456651 @default.
• W2004280168 hasConcept C2781182431 @default.
• W2004280168 hasConcept C502942594 @default.
• W2004280168 hasConcept C55493867 @default.
• W2004280168 hasConcept C71924100 @default.
• W2004280168 hasConcept C86803240 @default.
• W2004280168 hasConceptScore W2004280168C104317684 @default.
• W2004280168 hasConceptScore W2004280168C121608353 @default.
• W2004280168 hasConceptScore W2004280168C123321153 @default.
• W2004280168 hasConceptScore W2004280168C126322002 @default.
• W2004280168 hasConceptScore W2004280168C143065580 @default.
• W2004280168 hasConceptScore W2004280168C143998085 @default.
• W2004280168 hasConceptScore W2004280168C207583985 @default.
• W2004280168 hasConceptScore W2004280168C2776256026 @default.
• W2004280168 hasConceptScore W2004280168C2776694085 @default.
• W2004280168 hasConceptScore W2004280168C2777240266 @default.
• W2004280168 hasConceptScore W2004280168C2778239845 @default.
• W2004280168 hasConceptScore W2004280168C2779438470 @default.
• W2004280168 hasConceptScore W2004280168C2780456651 @default.
• W2004280168 hasConceptScore W2004280168C2781182431 @default.
• W2004280168 hasConceptScore W2004280168C502942594 @default.
• W2004280168 hasConceptScore W2004280168C55493867 @default.
• W2004280168 hasConceptScore W2004280168C71924100 @default.
• W2004280168 hasConceptScore W2004280168C86803240 @default.
• W2004280168 hasIssue "2" @default.
• W2004280168 hasLocation W20042801681 @default.
• W2004280168 hasLocation W20042801682 @default.

• next